Treatment of myeloproliferative neoplasms (MPNs) has historically focused on delaying or avoiding transformation to acute myeloid leukemia (AML) as well as symptom relief and improving quality of life; strategies addressed thrombosis or enlarged spleen both with therapy and with nonpharmacological […]
Exploring Possibilities in Disease Modification in MPNs Read More »
The symptoms of myeloproliferative neoplasms can be variable and common, which can make it difficult to diagnose if you aren’t looking for the right thing, said Ruben Mesa, MD, FACP, executive director of Atrium Health Wake Forest Baptist Comprehensive Cancer
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges Read More »
Early voting in the 2024 US presidential election is now under way in all 50 states. Although abortion has been a front burner issue in the race between Vice President Kamala Harris, a Democrat, and former President Donald Trump, a
5 Hot Health Care Topics in the Presidential Election Read More »
An updated meta-analysis confirms that ruxolitinib, the Janus kinase (JAK) 1/JAK2 inhibitor sold as Jakafi, offers improvements in key measures of efficacy compared with best available therapy (BAT) for patients with polycythemia vera (PV),1 a rare, slow-progressing disorder that causes
Ruxolitinib Beats Best Available Therapy in Treating Polycythemia Vera Read More »
When it was founded in July 2020, Thyme Care’s early focus in cancer care was patient navigation. By the fall of 2023, the company was serving more than 3000 patients1 and had research to show that its technology-driven navigation and
Thyme Care Ready for Heavy Lifts to Make Value-Based Care Work Read More »
On August 27, 2024, Thyme Care announced an appointment that had been rumored for weeks: Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, would join Thyme Care in Nashville, Tennessee, as senior vice president of value-based care.1 Wilfong’s
Wilfong Moves to Thyme Care Read More »
FDA today approved marstacimab, an anti-tissue factor pathway inhibitor (anti-TFPI) to prevent or reduce bleeding episodes in patients with hemophilia A and B. Marstacimab, to be sold as Hympavzi by Pfizer, is given weekly by an autoinjector pen and is
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B Read More »
The wonders of chimeric antigen receptor (CAR) T-cell therapy cannot escape a simple fact: for some patients, the wait required for the manufacturing process is simply too long. For years now, investigators have explored allogeneic CAR T-cell treatments, made with
An Off-the-Shelf CAR T Therapy for Myeloma Read More »
As choices and combinations in multiple myeloma proliferate, it’s good news for both patients and physicians, according to Ajai Chari, MD, professor of medicine at the University of California, San Francisco, who opened Friday’s symposium on immunotherapy at the International
From CARs to Trispecifics, More Choices to Come in Multiple Myeloma Read More »
The decision by FDA’s Oncology Drug Advisory Committee to endorse use of testing for minimal residual disease (MRD) negativity as part of a composite end point in clinical trials is considered a watershed event for those who study and treat
How Do Community Oncologists View the Use of MRD Testing? Read More »
